Single shot antibiotic approved for skin infections


Intravenous antibiotic Orbactiv (oritavancin), from US firm The Medicines Company, has been approved by the US Food and Drug Administration (FDA). The drug can be used to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Orbactiv is the third drug to be approved (all for ABSSSIs) under the FDA’s incentive programme for encouraging companies to develop new antibiotics. It joins Durata Therapeutics' Dalvance (dalbavancin), which was approved in May, and Cubist’s Sivextro (tedizolid), approved in June. All three were designated as Qualified Infectious Disease Products, since they combat pathogens on the FDA’s list of serious or life-threatening infections. That designation entitles the companies to speedier reviews of their regulatory applications, as well as an extra five years’ market exclusivity to take into account the restricted use of new antibiotics limiting sales.

Orbactiv and Dalvance are intravenous drugs with structures related to the current drug of last resort, vancomycin. Both are administered intravenously – Orbactiv in a single dose, compared to three infusions of Dalvance or 7–10 days of twice-daily vancomycin infusions. Sivextro is approved for both oral and intravenous use.


Related Content

Pepping up antibiotics

29 September 2014 Premium contentFeature

news image

Industry and academia are turning to antimicrobial peptides to find new antibiotics, Andy Extance discovers

Re-arming the antibiotic arsenal

26 September 2013 Feature

news image

How can we make new antibiotics? Phillip Broadwith takes a look

Most Commented

Undeniable: evolution and the science of creation

7 January 2015 Review

news image

Evolutionary arguments

Alkali metal explosion explained

26 January 2015 Research

news image

High-speed cameras help re-examine the chemistry behind a classic classroom demonstration